Nakanishi Y - Search Results

1

A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.

Harada T, Hamada A, Shimokawa M, Takayama K, Kudoh S, Maeno K, Saeki S, Miyawaki H, Moriyama A, Nakagawa K, Nakanishi Y. Harada T, et al. Among authors: nakanishi y. Jpn J Clin Oncol. 2014 Feb;44(2):127-33. doi: 10.1093/jjco/hyt198. Epub 2013 Dec 29. Jpn J Clin Oncol. 2014. PMID: 24379211 Clinical Trial.

2

Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.

Nakanishi Y, Takayama K, Kawasaki M, Yatsunami J, Inutsuka S, Wakamatsu K, Tsuruta N, Hara N. Nakanishi Y, et al. Am J Clin Oncol. 1997 Aug;20(4):393-7. doi: 10.1097/00000421-199708000-00015. Am J Clin Oncol. 1997. PMID: 9256897 Clinical Trial.

3

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.

Nakanishi Y, Takayama K, Takano K, Inoue K, Osaki S, Wataya H, Takaki Y, Minami T, Kawasaki M, Hara N. Nakanishi Y, et al. Am J Clin Oncol. 1999 Aug;22(4):399-402. doi: 10.1097/00000421-199908000-00016. Am J Clin Oncol. 1999. PMID: 10440199 Clinical Trial.

4

Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.

Nakanishi Y, Kawasaki M, Bai F, Takayama K, Pei XH, Takano K, Inoue K, Osaki S, Hara N, Kiyohara C. Nakanishi Y, et al. Oncology. 1999 Nov;57(4):318-23. doi: 10.1159/000012068. Oncology. 1999. PMID: 10575319

5

[Gene therapy for lung cancer treatment].

Takayama K, Nakanishi Y, Hara N. Takayama K, et al. Among authors: nakanishi y. Nihon Rinsho. 2000 May;58(5):1048-52. Nihon Rinsho. 2000. PMID: 10824547 Review. Japanese.

6

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Azuma K, et al. Among authors: nakanishi y. Ann Oncol. 2014 Oct;25(10):1935-1940. doi: 10.1093/annonc/mdu242. Epub 2014 Jul 9. Ann Oncol. 2014. PMID: 25009014 Free article.

7

G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.

Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Hara N. Pei XH, et al. Among authors: nakanishi y. Clin Exp Metastasis. 1998 Aug;16(6):551-8. doi: 10.1023/a:1006546402703. Clin Exp Metastasis. 1998. PMID: 9872602

8

Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.

Takayama K, Ogata K, Nakanishi Y, Yatsunami J, Kawasaki M, Hara N. Takayama K, et al. Among authors: nakanishi y. Cancer J Sci Am. 1996 Jul-Aug;2(4):212-6. Cancer J Sci Am. 1996. PMID: 9166534

9

Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.

Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, Hara N. Osaki S, et al. Among authors: nakanishi y. Cancer Gene Ther. 2000 Feb;7(2):300-7. doi: 10.1038/sj.cgt.7700096. Cancer Gene Ther. 2000. PMID: 10770640

10

Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan.

Uchino J, Takayama K, Harada A, Sone T, Harada T, Curiel DT, Kuroki M, Nakanishi Y. Uchino J, et al. Among authors: nakanishi y. Cancer Gene Ther. 2008 Feb;15(2):94-100. doi: 10.1038/sj.cgt.7701100. Epub 2007 Dec 21. Cancer Gene Ther. 2008. PMID: 18157147

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,334 results

Search Page

Filters